Emcure Pharma, Sanofi ink pact for oral anti-diabetic product distribution in India

Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that includes brands like Amaryl and Cetapin, the two companies said in a joint statement.

"With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them," Emcure Pharmaceuticals CEO and MD Satish Mehta said.

Further, he said, "This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country."

Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, "With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both—the patients who need them and the healthcare professionals who trust and prescribe them."

The two companies said there would be no people transitioning from Sanofi India to Emcure under their distribution and promotion agreement.

Shares of Emcure Pharma had marginal gains on Wednesday at ₹1,362.80 apiece, rising 0.09%, while Sanofi India shares tumbled 1.43% to close at ₹5,882.50 apiece on the National Stock Exchange.

Emcure Pharmaceuticals had reported a 63% rise in consolidated profit after tax (PAT) to ₹197 crore during the March quarter. The Pune-headquartered firm reported a PAT of ₹121 crore a year ago.

During the January-March period, Emcure Pharmaceuticals' revenue from operations stood at ₹2,116 crore, up 19.5% year-on-year from ₹1,771 crore logged in the corresponding quarter of the previous fiscal year.

The company saw strong performance across both its domestic and international businesses during the quarter.

Emcure's domestic business grew 24.8% year-on-year, led by its women's health and cardio franchises. Meanwhile, the international business registered a growth of 15.6%.